{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:57:17Z","timestamp":1768517837564,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Objective<\/jats:title>\n This study aims to identify the risk factors associated with gastrointestinal adverse events induced by semaglutide in patients with type 2 diabetes mellitus (T2DM) and to develop a predictive risk model.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 215 patients with T2DM admitted to our hospital between June 2022 and December 2024 were enrolled. Participants were divided into two groups based on the presence (\n n<\/jats:italic>\n \u00a0=\u00a041) or absence (\n n<\/jats:italic>\n \u00a0=\u00a0174) of gastrointestinal adverse events associated with semaglutide use. Univariate and multivariate logistic regression analyses were performed to identify significant risk factors for these adverse events. Subsequently, a nomogram was developed using R software to predict the likelihood of gastrointestinal adverse events in this patient population. The predictive performance of the nomogram was assessed using receiver operating characteristic (ROC) curves, calibration plots, and the Hosmer\u2013Lemeshow goodness-of-fit test.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In a cohort of 215 patients with T2DM, 41 individuals (19.07%) experienced gastrointestinal adverse events attributed to semaglutide administration. Logistic regression analysis identified concomitant gastrointestinal disorders [95% confidence interval (CI): 2.074\u20139.808,\n P<\/jats:italic>\n &lt;\u00a00.001], alcohol consumption (95% CI: 1.304\u20136.633,\n P<\/jats:italic>\n =\u00a00.009), and concurrent use of \u03b1-glucosidase inhibitors (95% CI: 1.368\u20136.460,\n P<\/jats:italic>\n =\u00a00.006) as independent risk factors for semaglutide-induced gastrointestinal adverse events in this population. The predictive model demonstrated an area under the ROC curve of 0.763 (95% CI: 0.691\u20130.836). Calibration assessment revealed a slope approximating unity, and the Hosmer\u2013Lemeshow goodness-of-fit test indicated an adequate model fit (\u03c7\u00b2 = 5.633,\n P<\/jats:italic>\n =\u00a00.228).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Patients with T2DM exhibit a significant incidence of gastrointestinal adverse events associated with semaglutide use. The presence of gastrointestinal comorbidities, alcohol consumption, and \u03b1-glucosidase inhibitor therapy are independent risk factors. The developed nomogram effectively predicts the likelihood of semaglutide-related gastrointestinal adverse events in this patient population.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2025.1684395","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:32Z","timestamp":1762147292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus"],"prefix":"10.3389","volume":"16","author":[{"given":"Deyong","family":"Yue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesheng","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenle","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoliang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01012-8","article-title":"Understanding the drivers and consequences of early-onset type 2 diabetes","volume":"405","author":"Lim","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s42255-024-01190-w","article-title":"Diabetes in China: epidemiology, pathophysiology and multi-omics","volume":"7","author":"Jia","year":"2025","journal-title":"Nat Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.05.013","article-title":"An update on the epidemiology of type 2 diabetes: A global perspective","volume":"50","author":"Tinajero","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1549945","article-title":"Immune cell contribution to vascular complications in diabetes","volume":"16","author":"Ma","year":"2025","journal-title":"Front Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00877-z","article-title":"Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention","volume":"20","author":"Wong","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: New pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2483","article-title":"Efficacy and safety of oral semaglutide in the treatment of type 2 diabetes: A meta-analysis","volume":"4","author":"Zhang","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ph18071058","article-title":"Weight loss effects of once-weekly semaglutide 2.4 mg in adults with and without type 2 diabetes: A systematic review and meta-analysis","volume":"18","author":"Hong","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: Findings from SUSTAIN 6 and PIONEER 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11684-021-0873-2","article-title":"New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation","volume":"16","author":"Liu","year":"2022","journal-title":"Front Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123328","article-title":"Semaglutide alleviates the pancreatic \u03b2 cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice","volume":"361","author":"Luo","year":"2025","journal-title":"Life Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17327","article-title":"Semaglutide protects against diabetes-associated cardiac inflammation via Sirt3-dependent RKIP pathway","volume":"182","author":"Lin","year":"2025","journal-title":"Br J Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16642","article-title":"Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes","volume":"27","author":"Sarwal","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: To ensure its optimal positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e70135","DOI":"10.1111\/1753-0407.70135","article-title":"Construction and implications of nomogram for predicting sustained glycemic remission after short-term intensive insulin therapy in newly diagnosed type 2 diabetes","volume":"17","author":"Xu","year":"2025","journal-title":"J Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1510147","article-title":"Construction and validation of a presenteeism prediction model for ICU nurses in China","volume":"13","author":"Wu","year":"2025","journal-title":"Front Public Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy13020055","article-title":"Heparin-induced hyperkalemia assessment utilizing the Naranjo Adverse Drug Reaction Probability Scale: A 40-year systematic review","volume":"13","author":"Singh","year":"2025","journal-title":"Pharmacy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1572725","article-title":"Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024)","volume":"15","author":"Shen","year":"2025","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1497750","article-title":"Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications","volume":"11","author":"Ebrahimi","year":"2025","journal-title":"Front Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1055\/a-2569-7315","article-title":"Efficacy, safety, and future of GLP-1 receptor agonists: A systematic literature review and meta-analysis","volume":"57","author":"Katz","year":"2025","journal-title":"Horm Metab Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1509947","article-title":"Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"12","author":"Huang","year":"2025","journal-title":"Front Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: Systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00053.2024","article-title":"Recent advances in alcohol metabolism: from the gut to the brain","volume":"105","author":"Goldman","year":"2025","journal-title":"Physiol Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2174\/1568026622666220831092855","article-title":"Recent advances of \u03b1-glucosidase inhibitors: A comprehensive review","volume":"22","author":"Agrawal","year":"2022","journal-title":"Curr Top Med Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-2425","article-title":"High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: A randomized, placebo-controlled, phase 2 trial","volume":"48","author":"Aroda","year":"2025","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969","article-title":"Semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1684395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:32Z","timestamp":1762147292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1684395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":32,"alternative-id":["10.3389\/fendo.2025.1684395"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1684395","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1684395"}}